NCT03317899View on ClinicalTrials.gov

Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

76

Participants

Timeline

Start Date

October 12, 2017

Primary Completion Date

June 1, 2021

Study Completion Date

November 16, 2022

Conditions
Non-Hodgkin's LymphomaPlasma Cell Myeloma
Interventions
PROCEDURE

Hematopoietic Cell Transplantation

Undergo auto HSCT

DRUG

Tbo-filgrastim

Given subcutaneously

OTHER

Laboratory Biomarker Analysis

Correlative Studies

Trial Locations (1)

19107

Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia

All Listed Sponsors
lead

Sidney Kimmel Cancer Center at Thomas Jefferson University

OTHER

NCT03317899 - Stem Cell Transplant With or Without Tbo-filgrastim in Treating Patients With Multiple Myeloma or Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter